BriaCell Therapeutics Completes $13.8 Million Public Offering

BriaCell Therapeutics Corp., a biotechnology company headquartered in PHILADELPHIA and VANCOUVER, British Columbia, has announced the successful completion of its public offering. The company, listed on Nasdaq as BCTX and BCTXZ and on the TSX as BCT, is at the forefront of developing innovative immunotherapies aimed at advancing cancer treatment. The recent public offering involved the sale of 3,066,666 units, including an additional 399,999 units sold as a result of the full exercise of the underwriter’s option to purchase more units. Each unit, priced at $4.50, consists of one common share or a pre-funded warrant and an additional warrant.

The total proceeds from this offering reached approximately $13.8 million, prior to the deduction of underwriting discounts and associated expenses. The warrants included in these units have been approved for trading on the Nasdaq Capital Market under the symbol BCTXZ starting April 25, 2025. These warrants can be exercised immediately and provide the holder the right to purchase one common share at a price of $5.25 per share. However, this option expires five years after the issue date.

BriaCell intends to allocate the net proceeds from this offering toward fulfilling working capital requirements, general corporate purposes, and advancing its business goals. The exemption outlined in Section 602.1 of the TSX Company Manual, which applies to certain transactions involving eligible issuers interlisted on recognized exchanges like Nasdaq, has been relied upon by the company.

ThinkEquity took on the role of the sole book-running manager for this offering. The registration statement on Form S-1, which is related to the securities and was filed with the Securities and Exchange Commission (SEC), became effective on April 24, 2025. A related registration statement was also filed under Rule 462(b) of the Securities Act of 1933. The offering was exclusively made via a prospectus, with final copies of the prospectus available from ThinkEquity and filed with the SEC.

It is important to note that this announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities. There will be no sale of these securities in any jurisdiction where such actions are deemed unlawful prior to registration or qualification under the relevant securities laws.

As a clinical-stage biotechnology firm, BriaCell is committed to transforming cancer care through cutting-edge immunotherapy solutions. The company continues to focus on its mission to improve the lives of cancer patients by developing therapies that harness the body’s immune system to combat cancer effectively.